Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study.
Male gender
Prothrombin 19911 A>G polymorphism
Recurrence
Thrombosis
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
pubmed:
1
7
2020
medline:
26
10
2021
entrez:
29
6
2020
Statut:
ppublish
Résumé
The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thrombophilias [IT], age at onset and blood group [BG], and to calculate the risk of VTE recurrence. We investigated 1012 Caucasian patients with a diagnosis of VTE for the presence of the F2 rs3136516 polymorphism and compared these with 902 healthy blood donors. Odds ratios [OR] together with their 95% confidence intervals were calculated adjusted for F5 at rs6025, F2 at rs1799963, blood group, age and gender. In addition, we evaluated the risk of recurrent VTE during patient follow-up calculating hazard ratios [HR] together with their 95% CI. Compared with the AA wildtype, the F2 GG and AG genotypes (rs3136516) were associated with VTE (OR 1.48 and 1.45). The OR in F5 carriers compared to controls was 5.68 and 2.38 in patients with F2 (rs1799963). BG "non-O" was significantly more often diagnosed in patients compared to BG "O" (OR 2.74). VTE recurrence more often occurred in males (HR 2.3) and in carriers with combined thrombophilia (HR 2.11). Noteworthy, the rs3136516 polymorphism alone was not associated significantly with recurrence. In Caucasian patients with VTE the F2 GG/GA genotypes (rs3136516) were moderate risk factors for VTE. Recurrence was associated with male gender and combined thrombophilia.
Identifiants
pubmed: 32594420
doi: 10.1007/s11239-020-02169-6
pii: 10.1007/s11239-020-02169-6
pmc: PMC7886710
doi:
Substances chimiques
Blood Group Antigens
0
Prothrombin
9001-26-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
494-501Subventions
Organisme : Interdisziplinäres Zentrum für Klinische Forschung
ID : IZKF: CRA01-09
Organisme : Gesellschaft für Thrombose und Hämostaseforschung/ Society of Thrombosis and Hemostasis Research" (GTH)
ID : GTH 2016
Commentaires et corrections
Type : ErratumIn
Références
Transl Res. 2015 May;165(5):537-48
pubmed: 25639953
Nature. 1994 May 5;369(6475):64-7
pubmed: 8164741
Lancet. 2006 Jul 29;368(9533):371-8
pubmed: 16876665
Blood. 2019 Nov 7;134(19):1645-1657
pubmed: 31420334
Thromb Haemost. 2001 Jun;85(6):1066-70
pubmed: 11434686
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1992-7
pubmed: 15976329
Chest. 2012 Feb;141(2 Suppl):e737S-e801S
pubmed: 22315277
J Thromb Haemost. 2006 Dec;4(12):2587-92
pubmed: 17059428
Arch Intern Med. 1991 May;151(5):933-8
pubmed: 2025141
Blood. 1996 Nov 15;88(10):3698-703
pubmed: 8916933
Am J Hematol. 2012 May;87 Suppl 1:S63-7
pubmed: 22367958
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Haematologica. 2019 Aug;104(8):1676-1681
pubmed: 30679327
Lancet. 1999 Apr 3;353(9159):1167-73
pubmed: 10209995
Blood Cells Mol Dis. 2017 Sep;67:2-13
pubmed: 28017497
Ann Neurol. 2009 Dec;66(6):754-8
pubmed: 20033984
Thromb Haemost. 2001 Jul;86(1):395-403
pubmed: 11487029
Blood. 2000 May 1;95(9):2780-5
pubmed: 10779421
BMJ. 2011 Feb 24;342:d813
pubmed: 21349898
Balkan J Med Genet. 2015 Apr 10;17(2):43-8
pubmed: 25937797
Blood. 2012 Aug 16;120(7):1510-5
pubmed: 22581447
J Thromb Haemost. 2006 Dec;4(12):2582-6
pubmed: 16981886
Thromb Haemost. 2014 Dec;112(6):1103-9
pubmed: 25187297
J Thromb Haemost. 2019 Jul;17(7):1144-1152
pubmed: 31033194
Lancet. 2000 May 6;355(9215):1627-32
pubmed: 10821379
Br J Haematol. 2002 Aug;118(2):610-4
pubmed: 12139755